@trevorpeekmma's BPC-157 claims about UFC fighters checked

What did @trevorpeekmma actually say?

UFC fighter Trevor Peek is frustrated, and he's not hiding it. Sitting with a swollen ankle and a sore wrist, he made a direct plea to UFC brass, including anti-doping chief Jeff Novitzky, to lift the ban on BPC-157 for fighters. His core argument: "there's no anabolic benefits to it, it doesn't enhance your performance," and fighters are entering the cage injured because they can't access something that could accelerate healing. He also noted that multiple doctors recommended BPC-157 to him directly, and he's had to decline every time due to UFC policy.

This is a legitimate policy debate. Peek is not selling supplements or making wild therapeutic promises. He's a working fighter describing a real occupational health gap. That context matters when evaluating the claims.

Does the science back this up?

The honest answer is: partially, and the gaps are significant. BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. The regenerative effects are real in animal models. The human evidence is nearly nonexistent.

Seiwerth et al. (2014, Current Pharmaceutical Design) and multiple subsequent animal studies showed accelerated tendon, ligament, and muscle healing in rodent models. The mechanisms, including upregulation of growth hormone receptor expression and nitric oxide pathway modulation, are biologically plausible. Chang et al. (2011, Journal of Applied Physiology) demonstrated improved Achilles tendon healing in rats. These are genuinely encouraging signals.

But here is the problem: as of 2024, there are no completed Phase II or Phase III randomized controlled trials in humans for musculoskeletal healing. The FDA has not approved BPC-157 for any indication. WADA and USADA have flagged it as a prohibited peptide, and the UFC's anti-doping program aligns with USADA standards. Peek's claim that the science is settled enough to green-light use is ahead of the evidence.

What did they get wrong (or right)?

Peek gets credit for one thing: the "no anabolic benefits" claim is largely defensible. BPC-157 does not appear to act through androgen receptor pathways the way traditional anabolic steroids do. It is not structurally or mechanistically similar to testosterone or growth hormone secretagogues. Krivic et al. (2008, Journal of Orthopaedic Research) found no muscle hypertrophy signals in their tendon repair models. So the argument that it is categorically different from performance-enhancing drugs has some scientific grounding.

Where he goes wrong, or at least overstates things, is the implied certainty that BPC-157 is proven safe and effective for human recovery. Saying fighters are "in more danger without it" is an emotional argument, not a clinical one. We do not have human dose-response data, long-term safety profiles in athletic populations, or reliable bioavailability data for oral versus injectable forms. The leap from "animal studies look good" to "fighters should have access" skips several steps that exist for real reasons.

His comparison to medications with established "shelf life" protocols also conflates very different regulatory categories.

What should you actually know?

BPC-157 sits in a genuinely ambiguous regulatory space. It is not a controlled substance in the United States. It has been available through compounding pharmacies, though the FDA issued guidance in 2023 restricting compounded BPC-157, citing lack of clinical evidence. This means the landscape for access has actually narrowed, not expanded, in recent years.

The UFC's prohibition follows USADA guidelines, which ban peptide hormones and related substances broadly, partly because detection windows are short and partly because the class of compounds includes agents with clearer performance-enhancement potential. Lumping BPC-157 into that category is a blunt instrument, and Peek's frustration about that is understandable.

What fighters and coaches should know: the regenerative science is promising but unproven in humans. Anyone using BPC-157 outside a supervised clinical context is essentially self-experimenting with incomplete safety data. The doctors recommending it to Peek are working from animal data and clinical intuition, not a robust evidence base. That does not make them wrong, but it does mean the confidence level should be lower than Peek's video implies.

The policy question of whether prohibition is proportionate given BPC-157's apparent mechanism is a fair one. The scientific question of whether it actually works in humans the way everyone hopes is still open.